The estimated Net Worth of Kenneth I Kaitin is at least $159 Tysiąc dollars as of 23 January 2019. Kenneth Kaitin owns over 14,800 units of Curis Inc stock worth over $143,417 and over the last 21 years he sold CRIS stock worth over $15,540. In addition, he makes $0 as Independent Director at Curis Inc.
Kenneth has made over 4 trades of the Curis Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 14,800 units of CRIS stock worth $15,540 on 23 January 2019.
The largest trade he's ever made was exercising 15,000 units of Curis Inc stock on 31 May 2017 worth over $20,850. On average, Kenneth trades about 1,985 units every 108 days since 2003. As of 23 January 2019 he still owns at least 28,121 units of Curis Inc stock.
You can see the complete history of Kenneth Kaitin stock trades at the bottom of the page.
Dr. Kenneth I. Kaitin Ph.D. serves as Independent Director of the Company. serves as Independent Director of the Company. Since July 1998, Dr. Kaitin has been the Director of the Tufts Center for the Study of Drug Development, an academic drug policy research group providing strategic information to help drug developers, regulators, and policy makers improve the quality and efficiency of the drug development process. Since August 2014, Dr. Kaitin has held a primary appointment as Professor of Public Health and Community Medicine at the Tufts University School of Medicine, as well as secondary appointments as Professor of Medicine and Professor of Integrative Physiology and Pathobiology at Tufts University School of Medicine. In December 2014, Dr. Kaitin received the appointment of Advisory Professor at Shanghai Medical College of Fudan University. Since September 1999, he has served on the faculty of the European Center for Pharmaceutical Medicine at the University of Basel, and since April 2006 he has been a Visiting Executive at the Tuck School of Business at Dartmouth College. At the Tufts University School of Medicine, Dr. Kaitin was a Research Associate Professor of Medicine from October 2003 to May 2008 and a Research Professor from May 2008 to August 2014. Dr. Kaitin has written extensively on a broad range of drug development issues and has provided public testimony before the U.S. Congress in hearings on pharmaceutical innovation and FDA reform. An internationally recognized expert on the science of drug development, Dr. Kaitin is regularly quoted in the business and trade press on R&D trends in the research-based drug industry and new models of innovation. In 2011, Dr. Kaitin received the Dr. Louis M. Sherwood Award granted by the Academy of Pharmaceutical Physicians and Investigators. Dr. Kaitin received an M.S. and Ph.D. in pharmacology from the University of Rochester and a B.S. from Cornell University.
Kenneth Kaitin is 67, he's been the Independent Director of Curis Inc since 2003. There are 1 older and 9 younger executives at Curis Inc. The oldest executive at Curis Inc is Martyn Greenacre, 78, who is the Independent Chairman of the Board.
Kenneth's mailing address filed with the SEC is 128 SPRING STREET, BUILDING C - SUITE 500, LEXINGTON, MA, 02421.
Over the last 24 years, insiders at Curis Inc have traded over $10,321,234 worth of Curis Inc stock and bought 10,678,594 units worth $25,596,192 . The most active insiders traders include Partners L P/Ilbiotechnolog..., Discovery Technologies Ltd ... oraz James R Mcnab. On average, Curis Inc executives and independent directors trade stock every 62 days with the average trade being worth of $811,553. The most recent stock trade was executed by James E Dentzer on 27 January 2022, trading 5,500 units of CRIS stock currently worth $17,160.
curis is a publicly-traded biotechnology company (nasdaq: cris) focused on the development and commercialization of innovative drug candidates for the treatment of human cancers. curis’s pipeline of drug candidates includes cudc-907, which is currently being investigating in clinical trials in patients with relapsed or refractory diffuse large b-cell lymphoma with alterations in the myc oncogene. curis is also engaged in a broad collaboration with aurigene in the areas of immuno-oncology and precision oncology. as part of this collaboration, curis has exclusive licenses to oral small molecule antagonists of the pd1 and vista pathways, including pdl1/vista antagonist ca-170, and oral small molecule antagonists of the pd1 and tim3 pathways, including pdl1/tim3 antagonist ca-327, as well as to molecules designed to inhibit the irak4 kinase, including ca-4948. ca-170 is currently undergoing testing in a phase 1 trial in patients with advanced solid tumors and lymphomas. ca-4948 is currentl
Curis Inc executives and other stock owners filed with the SEC include: